More than half a million thyroid nodules will be detected and tested for cancer this year alone. And a disproportionate amount will be found in women, which is why researchers with Interpace Diagnostics are eager for two new tests to hit the market this spring. “It’s ThyraMIR which is a rule out test in combination […]
More than half a million thyroid nodules will be detected and tested for cancer this year alone. And a disproportionate amount will be found in women, which is why researchers with Interpace Diagnostics are eager for two new tests to hit the market this spring.
“It’s ThyraMIR which is a rule out test in combination with ThyGenX which is a rule in test,” said Interpace Diagnostics CEO Nancy Lurker.
Read the Full Story
